PROTAC-mediated degradation of class I histone deacetylase enzymes in corepressor complexes

Erasers of Histone Acetylation: The Histone Deacetylase EnzymesPreprint

Seto, E., & Yoshida, M. (2014) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a018713 · Cited by 2,019 · see citing works

Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders

Falkenberg, K. J., & Johnstone, R. W. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4360 · Cited by 1,564 · see citing works

Structural basis of PROTAC cooperative recognition for selective protein degradation

Gadd, M. S., Testa, A., Lucas, X., Chan, K.-H., Chen, W., Lamont, D. J., Zengerle, M., & Ciulli, A. (2017) · Nature Chemical Biology · doi:10.1038/nchembio.2329 · Cited by 1,242 · see citing works

Proteolysis-Targeting Chimeras as Therapeutics and Tools for Biological Discovery

Burslem, G. M., & Crews, C. M. (2020) · Cell · doi:10.1016/j.cell.2019.11.031 · Cited by 1,079 · see citing works

Selective Small Molecule Induced Degradation of the BET Bromodomain Protein BRD4

Zengerle, M., Chan, K.-H., & Ciulli, A. (2015) · ACS Chemical Biology · doi:10.1021/acschembio.5b00216 · Cited by 1,056 · see citing works

Lessons in PROTAC Design from Selective Degradation with a Promiscuous Warhead

Bondeson, D. P., Smith, B. E., Burslem, G. M., Buhimschi, A. D., Hines, J., Jaime-Figueroa, S., Wang, J., Hamman, B. D., Ishchenko, A., & Crews, C. M. (2018) · Cell Chemical Biology · doi:10.1016/j.chembiol.2017.09.010 · Cited by 923 · see citing works

PROteolysis TArgeting Chimeras (PROTACs) — Past, present and future

Pettersson, M., & Crews, C. M. (2019) · Drug Discovery Today Technologies · doi:10.1016/j.ddtec.2019.01.002 · Cited by 818 · see citing works

Modular PROTAC design for the degradation of oncogenic BCR-ABL

Lai, A. C., Toure, M., Hellerschmied, D., Salami, J., Jaime‐Figueroa, S., Ko, E., Hines, J., & Crews, C. M. (2016) · Angewandte Chemie International Edition · doi:10.1002/anie.201507634 · Cited by 618 · see citing works

Differential PROTAC substrate specificity dictated by orientation of recruited E3 ligase

Smith, B. E., Wang, S. L., Jaime-Figueroa, S., Harbin, A., Wang, J., Hamman, B. D., & Crews, C. M. (2019) · Nature Communications · doi:10.1038/s41467-018-08027-7 · Cited by 517 · see citing works

HDAC and HDAC Inhibitor: From Cancer to Cardiovascular Diseases

Yoon, S., & Eom, G. H. (2016) · Chonnam Medical Journal · doi:10.4068/cmj.2016.52.1.1 · Cited by 469 · see citing works

Histone Deacetylase (HDAC) Inhibitor Kinetic Rate Constants Correlate with Cellular Histone Acetylation but Not Transcription and Cell Viability

Lauffer, B. E. L., Mintzer, R., Fong, R., Mukund, S., Tam, C., Zilberleyb, I., Flicke, B., Ritscher, A., Fedorowicz, G., Vallero, R., et al. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.490706 · Cited by 429 · see citing works

HDAC expression and clinical prognosis in human malignancies

Weichert, W. (2008) · Cancer Letters · doi:10.1016/j.canlet.2008.10.047 · Cited by 411 · see citing works

Epigenetic Priming of Memory Updating during Reconsolidation to Attenuate Remote Fear Memories

Gräff, J., Joseph, N. F., Horn, M. E., Samiei, A., Meng, J., Seo, J., Rei, D., Bero, A. W., Phan, T. X., Wagner, F., et al. (2014) · Cell · doi:10.1016/j.cell.2013.12.020 · Cited by 357 · see citing works

The timeline of epigenetic drug discovery: from reality to dreams

Ganesan, A., Arimondo, P. B., Rots, M. G., Jerónimo, C., & Berdasco, M. (2019) · Clinical Epigenetics · doi:10.1186/s13148-019-0776-0 · Cited by 342 · see citing works

Histone deacetylase 1 (HDAC1), but not HDAC2, controls embryonic stem cell differentiation

Dovey, O. M., Foster, C. T., & Cowley, S. M. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1000478107 · Cited by 298 · see citing works

The physiological roles of histone deacetylase (HDAC) 1 and 2: complex co-stars with multiple leading parts

Kelly, R. D. W., & Cowley, S. M. (2013) · Biochemical Society Transactions · doi:10.1042/bst20130010 · Cited by 297 · see citing works

Molecular recognition of ternary complexes: a new dimension in the structure-guided design of chemical degraders

Hughes, S. J., & Ciulli, A. (2017) · Essays in Biochemistry · doi:10.1042/ebc20170041 · Cited by 240 · see citing works

Impact of linker length on the activity of PROTACs

Cyrus, K., Wehenkel, M., Choi, E.-Y., Han, H.-J., Lee, H., Swanson, H., & Kim, K.-B. (2010) · Molecular BioSystems · doi:10.1039/c0mb00074d · Cited by 232 · see citing works

Distinct pharmacological properties of second generation HDAC inhibitors with the benzamide or hydroxamate head group

Beckers, T. L., Burkhardt, C., Wieland, H., Gimmnich, P., Ciossek, T., Maier, T. M., & Sanders, K. (2007) · International Journal of Cancer · doi:10.1002/ijc.22751 · Cited by 191 · see citing works

Targeting Class I Histone Deacetylases in a “Complex” Environment

Millard, C. J., Watson, P. J., Fairall, L., & Schwabe, J. W. R. (2017) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2016.12.006 · Cited by 180 · see citing works

Development of Multifunctional Histone Deacetylase 6 Degraders with Potent Antimyeloma Activity

Wu, H., Yang, K., Zhang, Z., Leisten, E. D., Li, Z., Xie, H., Liu, J., Smith, K. A., Novakova, Z., Barinka, C., et al. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b00516 · Cited by 180 · see citing works

Physiological Roles of Class I HDAC Complex and Histone Demethylase

Hayakawa, T., & Nakayama, J. (2010) · BioMed Research International · doi:10.1155/2011/129383 · Cited by 165 · see citing works

Histone deacetylase (HDAC) 1 and 2 are essential for accurate cell division and the pluripotency of embryonic stem cells

Jamaladdin, S., Kelly, R. D., O’Regan, L., Dovey, O. M., Hodson, G. E., Millard, C. J., Portolano, N., Fry, A. M., Schwabe, J. W. R., & Cowley, S. M. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1321330111 · Cited by 164 · see citing works

Mechanism of Crosstalk between the LSD1 Demethylase and HDAC1 Deacetylase in the CoREST Complex

Song, Y., Dagil, L., Fairall, L., Robertson, N., Wu, M., Ragan, T. J., Savva, C. G., Saleh, A., Morone, N., Kunze, M. B. A., et al. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.01.091 · Cited by 141 · see citing works

Developing potent PROTACs tools for selective degradation of HDAC6 protein

An, Z., Lv, W., Su, S., Wu, W., & Rao, Y. (2019) · Protein & Cell · doi:10.1007/s13238-018-0602-z · Cited by 133 · see citing works

HDAC inhibitors still need a home run, despite recent approval

Guha, M. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4583 · Cited by 120 · see citing works

Class I histone deacetylase (HDAC) inhibitor CI-994 promotes functional recovery following spinal cord injury

Zhang, S., Fujita, Y., Matsuzaki, R., & Yamashita, T. (2018) · Cell Death & Disease · doi:10.1038/s41419-018-0543-8 · Cited by 68 · see citing works

Class I HDACs Affect DNA Replication, Repair, and Chromatin Structure: Implications for Cancer Therapy

Stengel, K. R., & Hiebert, S. W. (2014) · Antioxidants and Redox Signaling · doi:10.1089/ars.2014.5915 · Cited by 61 · see citing works

Preclinical antitumor activity of CI-994

LoRusso, P. M., Demchik, L. L., Foster, B. J., Knight, J., Bissery, M.-C., Polin, L., Leopold, W. R., & Corbett, T. H. (1996) · Investigational New Drugs · doi:10.1007/bf00180810 · Cited by 56 · see citing works

Class I Histone Deacetylase Inhibition for the Treatment of Sustained Atrial Fibrillation

Seki, M., LaCanna, R., Powers, J. C., Vrakas, C. N., Liu, F., Berretta, R. M., Chacko, G., Holten, J., Jadiya, P., Wang, T., et al. (2016) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.116.234591 · Cited by 38 · see citing works

H3K9ac and HDAC2 Activity Are Involved in the Expression of Monocarboxylate Transporter 1 in Oligodendrocyte

Lai, Q., Du, W., Wu, J. H., Wang, X., Li, X., Qu, X., Wu, X., Dong, F., Yao, R., & Fan, H. (2017) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2017.00376 · Cited by 27 · see citing works

Thirty Years of HDAC Inhibitors: 2020 Insight and Hindsight

Ho, T. C. S., Chan, A. H. Y., & Ganesan, A. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c00830 · Cited by 795 · see citing works

PROTACs: An Emerging Therapeutic Modality in Precision Medicine

Nalawansha, D. A., & Crews, C. M. (2020) · Cell chemical biology · doi:10.1016/j.chembiol.2020.07.020 · Cited by 514 · see citing works

Current strategies for the design of PROTAC linkers: a critical review

Troup, R. I., Fallan, C., & Baud, M. G. J. (2020) · Exploration of Targeted Anti-tumor Therapy · doi:10.37349/etat.2020.00018 · Cited by 424 · see citing works

Proteolysis-targeting chimeras (PROTACs) in cancer therapy

Li, X., Pu, W., Zheng, Q., Ai, M., Chen, S., & Peng, Y. (2022) · Molecular Cancer · doi:10.1186/s12943-021-01434-3 · Cited by 374 · see citing works

An overview of PROTACs: a promising drug discovery paradigm

Zi, L., Hu, M., Yu, Y., Du, C., Zhou, H., Liu, C., Chen, Y., Fan, L., Ma, H., Gong, Y., et al. (2022) · Molecular Biomedicine · doi:10.1186/s43556-022-00112-0 · Cited by 366 · see citing works

Targeted protein degradation: A promise for undruggable proteins

Samarasinghe, K. T. G., & Crews, C. M. (2021) · Cell chemical biology · doi:10.1016/j.chembiol.2021.04.011 · Cited by 291 · see citing works

PROTACs: great opportunities for academia and industry (an update from 2020 to 2021)

He, M., Cao, C., Ni, Z., Liu, Y., Song, P., Hao, S., He, Y., Sun, X., & Rao, Y. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-00999-9 · Cited by 283 · see citing works

Proteolysis targeting chimera (PROTAC) in drug discovery paradigm: Recent progress and future challenges

Zeng, S., Huang, W., Zheng, X., Cheng, L., Zhang, Z., Wang, J., & Shen, Z. (2020) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.112981 · Cited by 262 · see citing works

Targeting histone deacetylases for cancer therapy: Trends and challenges

Liang, T., Wang, F., Elhassan, R. M., Cheng, Y., Tang, X., Chen, W., Fang, H., & Hou, X. (2023) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2023.02.007 · Cited by 222 · see citing works

Anticancer Therapy with HDAC Inhibitors: Mechanism-Based Combination Strategies and Future Perspectives

Jenke, R., Reßing, N., Hansen, F. K., Aigner, A. M., & Büch, T. (2021) · Cancers · doi:10.3390/cancers13040634 · Cited by 194 · see citing works

Targeted degradation of the enhancer lysine acetyltransferases CBP and p300

Vannam, R., Sayilgan, J., Ojeda, S., Karakyriakou, B., Hu, E., Kreuzer, J., Morris, R., Herrera Lopez, X. I., Rai, S., Haas, W., et al. (2021) · Cell Chemical Biology · doi:10.1016/j.chembiol.2020.12.004 · Cited by 177 · see citing works

Developments of CRBN-based PROTACs as potential therapeutic agents

Wang, C., Zhang, Y., Wu, Y., & Xing, D. (2021) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2021.113749 · Cited by 152 · see citing works

Discovery of histone deacetylase 3 (HDAC3)-specific PROTACs

Xiao, Y., Wang, J., Zhao, L., Chen, X., Zheng, G., Zhang, X., & Liao, D. (2020) · Chemical Communications · doi:10.1039/d0cc03243c · Cited by 130 · see citing works

Proteolysis targeting chimeras (PROTACs) are emerging therapeutics for hematologic malignancies

He, Y., Khan, S., Huo, Z., Lv, D., Zhang, X., Liu, X., Yuan, Y., Hromas, R., Xu, M., Zheng, G., et al. (2020) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-00924-z · Cited by 126 · see citing works

A bibliometric analysis of PROTAC from 2001 to 2021

Li, D., Yu, D., Li, Y., & Yang, R. (2022) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2022.114838 · Cited by 122 · see citing works

Strategies for designing proteolysis targeting chimaeras (PROTACs)

He, S., Dong, G., Cheng, J., Wu, Y., & Sheng, C. (2022) · Medicinal Research Reviews · doi:10.1002/med.21877 · Cited by 118 · see citing works

HDAC-targeting epigenetic modulators for cancer immunotherapy

Cheng, B., Pan, W., Xiao, Y., Ding, Z., Zhou, Y., Fei, X., Liu, J., Su, Z., Peng, X., & Chen, J. (2024) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2024.116129 · Cited by 115 · see citing works

Annual review of PROTAC degraders as anticancer agents in 2022

Wang, X., Qin, Z.-L., Li, N., Jia, M.-Q., Liu, Q.-G., Bai, Y., Song, J., Yuan, S., & Zhang, S. (2024) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2024.116166 · Cited by 107 · see citing works

Chemo-proteomics exploration of HDAC degradability by small molecule degraders

Xiong, Y., Donovan, K. A., Eleuteri, N. A., Kirmani, N., Yue, H., Razov, A., Krupnick, N. M., Nowak, R. P., & Fischer, E. S. (2021) · Cell chemical biology · doi:10.1016/j.chembiol.2021.07.002 · Cited by 90 · see citing works

Medicinal chemistry updates of novel HDACs inhibitors (2020 to present)

He, X., Hui, Z., Xu, L., Bai, R., Gao, Y., Wang, Z., Xie, T., & Ye, X.-Y. (2022) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2021.113946 · Cited by 89 · see citing works

Overview of epigenetic degraders based on PROTAC, molecular glue, and hydrophobic tagging technologies

Peng, X., Hu, Z., Zeng, L., Zhang, M., Xu, C., Lu, B., Tao, C., Chen, W., Hou, W., Cheng, K., et al. (2023) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2023.09.003 · Cited by 85 · see citing works

Optimization of Class I Histone Deacetylase PROTACs Reveals that HDAC1/2 Degradation is Critical to Induce Apoptosis and Cell Arrest in Cancer Cells

Smalley, J. P., Baker, I. M., Pytel, W. A., Lin, L., Bowman, K. J., Schwabe, J. W. R., Cowley, S. M., & Hodgkinson, J. T. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c02179 · Cited by 84 · see citing works

HDAC Inhibitors: Innovative Strategies for Their Design and Applications

Daśko, M., de Pascual‐Teresa, B., Ortín, I., & Ramos, A. (2022) · Molecules · doi:10.3390/molecules27030715 · Cited by 80 · see citing works

Solid-Phase Synthesis of Cereblon-Recruiting Selective Histone Deacetylase 6 Degraders (HDAC6 PROTACs) with Antileukemic Activity

Sinatra, L., Yang, J. C., Schliehe‐Diecks, J., Dienstbier, N., Vogt, M., Gebing, P., Bachmann, L. M., Sönnichsen, M., Lenz, T., Stühler, K., et al. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c01659 · Cited by 74 · see citing works

Hydroxamic Acids Immobilized on Resins (HAIRs): Synthesis of Dual‐Targeting HDAC Inhibitors and HDAC Degraders (PROTACs)

Sinatra, L., Bandolik, J. J., Roatsch, M., Sönnichsen, M., Schoeder, C. T., Hamacher, A., Schöler, A., Borkhardt, A., Meiler, J., Bhatia, S., et al. (2020) · Angewandte Chemie International Edition · doi:10.1002/anie.202006725 · Cited by 73 · see citing works

VHL-based PROTACs as potential therapeutic agents: Recent progress and perspectives

Wang, C., Zhang, Y., Wang, J., & Xing, D. (2021) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2021.113906 · Cited by 71 · see citing works

Targeting Histone Deacetylases: Opportunities for Cancer Treatment and Chemoprevention

Ružić, D., Djoković, N., Srdić‐Rajić, T., Echeverría, C., Nikolic, K. M., & Santibanez, J. F. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14010209 · Cited by 67 · see citing works

Current trends in development of HDAC-based chemotherapeutics

Cheshmazar, N., Hamzeh‐Mivehroud, M., Charoudeh, H. N., Hemmati, S., Melesina, J., & Dastmalchi, S. (2022) · Life Sciences · doi:10.1016/j.lfs.2022.120946 · Cited by 57 · see citing works

Selective degradation of histone deacetylase 8 mediated by a proteolysis targeting chimera (PROTAC)

Chotitumnavee, J., Yamashita, Y., Takahashi, Y., Takada, Y., Iida, T., Oba, M., Itoh, Y., & Suzuki, T. (2022) · Chemical Communications · doi:10.1039/d2cc00272h · Cited by 57 · see citing works

HDAC3 and HDAC8 PROTAC dual degrader reveals roles of histone acetylation in gene regulation

Xiao, Y., Hale, S. M., Awasthee, N., Meng, C., Zhang, X., Liu, Y., Ding, H., Huo, Z., Lv, D., Zhang, W., et al. (2023) · Cell chemical biology · doi:10.1016/j.chembiol.2023.07.010 · Cited by 54 · see citing works

Bifunctional HDAC Therapeutics: One Drug to Rule Them All?

Smalley, J. P., Cowley, S. M., & Hodgkinson, J. T. (2020) · Molecules · doi:10.3390/molecules25194394 · Cited by 47 · see citing works

Discovery of pomalidomide-based PROTACs for selective degradation of histone deacetylase 8

Sun, Z., Deng, B., Yang, Z., Mai, R., Huang, J., Ma, Z., Chen, T., & Chen, J. (2022) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2022.114544 · Cited by 46 · see citing works

Design, Synthesis and Biological Characterization of Histone Deacetylase 8 (HDAC8) Proteolysis Targeting Chimeras (PROTACs) with Anti-Neuroblastoma Activity

Darwish, S., Ghazy, E., Heimburg, T., Herp, D., Zeyen, P., Salem-Altintas, R., Ridinger, J., Schmidtkunz, K., Robaa, D., Erdmann, F., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23147535 · Cited by 45 · see citing works

Degraders in epigenetic therapy: PROTACs and beyond

Dai, X., Ji, S., Fu, M., Liu, G.-Z., Liu, H., Wang, S., Shen, L., Wang, N., Herdewijn, P. A., Zheng, Y., et al. (2024) · Theranostics · doi:10.7150/thno.92526 · Cited by 44 · see citing works

The application of PROTAC in HDAC

Chen, S., Zheng, Y., Liang, B., Yin, Y., Yao, J., Wang, Q., Liu, Y., & Neamati, N. (2023) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2023.115746 · Cited by 43 · see citing works

Journey of Von Hippel-Lindau (VHL) E3 ligase in PROTACs design: From VHL ligands to VHL-based degraders

Setia, N., Almuqdadi, H. T. A., & Abid, M. (2023) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2023.116041 · Cited by 41 · see citing works

Discovery of highly potent HDAC8 PROTACs with anti-tumor activity

Zhao, C., Chen, D., Suo, F., Setroikromo, R., Quax, W. J., & Dekker, F. J. (2023) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2023.106546 · Cited by 40 · see citing works

PROTACs, molecular glues and bifunctionals from bench to bedside: Unlocking the clinical potential of catalytic drugs

Maneiro, M., Vita, E. D., Conole, D., Kounde, C. S., Zhang, Q., & Tate, E. W. (2021) · Progress in medicinal chemistry · doi:10.1016/bs.pmch.2021.01.002 · Cited by 38 · see citing works

Light-Controllable PROTACs for Temporospatial Control of Protein Degradation

Liu, J., Peng, Y., & Wei, W. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.678077 · Cited by 38 · see citing works

Designing HDAC-PROTACs: Lessons Learned So Far

Fischer, F., Avelar, L. A. A., Murray, L., & Kurz, T. (2021) · Future Medicinal Chemistry · doi:10.4155/fmc-2021-0206 · Cited by 38 · see citing works

PROTAC: targeted drug strategy. Principles and limitations

Koroleva, O. A., Dutikova, Y. V., Trubnikov, A. V., Zenov, F. A., Manasova, E. V., Shtil, A. A., & Kurkin, A. V. (2022) · Russian Chemical Bulletin · doi:10.1007/s11172-022-3659-z · Cited by 38 · see citing works

Chemically induced degradation of epigenetic targets

Kabir, M., Yu, X., Kanıskan, H. Ü., & Jin, J. J. (2023) · Chemical Society Reviews · doi:10.1039/d3cs00100h · Cited by 35 · see citing works

Collateral lethality between HDAC1 and HDAC2 exploits cancer-specific NuRD complex vulnerabilities

Zhang, Y., Remillard, D., Onubogu, U., Karakyriakou, B., Asiaban, J. N., Ramos, A. R., Bowland, K., Bishop, T. R., Barta, P. A., Nance, S., et al. (2023) · Nature Structural & Molecular Biology · doi:10.1038/s41594-023-01041-4 · Cited by 35 · see citing works

Overview of class I HDAC modulators: Inhibitors and degraders

Huang, Z., Zeng, L., Cheng, B., & Li, D. (2024) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2024.116696 · Cited by 34 · see citing works

Developing HDAC4-Selective Protein Degraders To Investigate the Role of HDAC4 in Huntington’s Disease Pathology

Macabuag, N., Esmieu, W., Breccia, P., Jarvis, R. E., Blackaby, W., Lazari, O., Urbonas, L., Eznarriaga, M., Williams, R., Strijbosch, A., et al. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c01149 · Cited by 34 · see citing works

An updated patent review of histone deacetylase (HDAC) inhibitors in cancer (2020 – present)

Liu, Y., & Liou, J. (2023) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2023.2219393 · Cited by 33 · see citing works

Comprehensive Transcriptomic Analysis of Novel Class I HDAC Proteolysis Targeting Chimeras (PROTACs)

Baker, I. M., Smalley, J. P., Sabat, K. A., Hodgkinson, J. T., & Cowley, S. M. (2022) · Biochemistry · doi:10.1021/acs.biochem.2c00288 · Cited by 32 · see citing works

Progress of small molecules for targeted protein degradation: PROTACs and other technologies

Zhao, H., Xin, M., & Zhang, S. (2023) · Drug Development Research · doi:10.1002/ddr.22026 · Cited by 31 · see citing works

Small-Molecule PROTACs for Cancer Immunotherapy

Liu, Z., Zhang, Y., Xiang, Y., & Kang, X. (2022) · Molecules · doi:10.3390/molecules27175439 · Cited by 29 · see citing works

T herapeutic targeting of chromatin: status and opportunities

Siklos, M. I., & Kubicek, S. (2021) · FEBS Journal · doi:10.1111/febs.15966 · Cited by 28 · see citing works

PROTACs in gastrointestinal cancers

Chen, Y., Yang, Q., Xu, J., Tang, L., Zhang, Y., Du, F., Zhao, Y., Wu, X., Li, M., Shen, J., et al. (2022) · Molecular Therapy — Oncolytics · doi:10.1016/j.omto.2022.10.012 · Cited by 28 · see citing works

A ‘click’ chemistry approach to novel entinostat (MS-275) based class I histone deacetylase proteolysis targeting chimeras

Cross, J. M., Coulson, M. E., Smalley, J. P., Pytel, W. A., Ismail, O., Trory, J. S., Cowley, S. M., & Hodgkinson, J. T. (2022) · RSC Medicinal Chemistry · doi:10.1039/d2md00199c · Cited by 27 · see citing works

Technologies of targeting histone deacetylase in drug discovery: Current progress and emerging prospects

Ru, J., Wang, Y., Li, Z., Wang, J., Ren, C., & Zhang, J. (2023) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2023.115800 · Cited by 27 · see citing works

Elucidation of genome-wide understudied proteins targeted by PROTAC-induced degradation using interpretable machine learning

Xie, L., & Xie, L. (2023) · PLOS Computational Biology · doi:10.1371/journal.pcbi.1010974 · Cited by 26 · see citing works

Recent advances in dual PROTACs degrader strategies for disease treatment

Liu, J., Liu, Y., Tang, J., Gong, Q., Yan, G., Fan, H., Zhang, X., & Pu, C. (2024) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2024.116901 · Cited by 25 · see citing works

Development of a Bestatin-SAHA Hybrid with Dual Inhibitory Activity against APN and HDAC

Cao, J., Zhao, W., Zhao, C., Liu, Q., Li, S., Zhang, G., Chou, C. J., & Zhang, Y. (2020) · Molecules · doi:10.3390/molecules25214991 · Cited by 24 · see citing works

Advances in the Design and Development of PROTAC-mediated HDAC Degradation

Rodrigues, D. A., Roe, A. J., Griffith, D. M., & Chonghaile, T. N. (2021) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026621666211015092047 · Cited by 24 · see citing works

PROTAC chemical probes for histone deacetylase enzymes

Patel, U., Smalley, J. P., & Hodgkinson, J. T. (2023) · RSC Chemical Biology · doi:10.1039/d3cb00105a · Cited by 24 · see citing works

Developments of PROTACs technology in immune-related diseases

Wang, C., Zhang, Y., Deng, J., Liang, B., & Xing, D. (2023) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2023.115127 · Cited by 23 · see citing works

Advances and Opportunities in Epigenetic Chemical Biology

Beyer, J. N., Raniszewski, N. R., & Burslem, G. M. (2020) · ChemBioChem · doi:10.1002/cbic.202000459 · Cited by 23 · see citing works

Recent advances in epigenetic proteolysis targeting chimeras (Epi-PROTACs)

Tomaselli, D., Mautone, N., Mai, A., & Rotili, D. (2020) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.112750 · Cited by 21 · see citing works

Targeting micro-environmental pathways by PROTACs as a therapeutic strategy

Liu, J., Peng, Y., Inuzuka, H., & Wei, W. (2022) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2022.07.001 · Cited by 20 · see citing works

Recent Advances in Small Molecular Modulators Targeting Histone Deacetylase 6

Xiao, Y., & Zhang, X. (2020) · Future Drug Discovery · doi:10.4155/fdd-2020-0023 · Cited by 20 · see citing works

Design, Synthesis, and Biological Evaluation of HDAC Degraders with CRBN E3 Ligase Ligands

Lu, Y., Sun, D., Xiao, D., Shao, Y.-Y., Su, M., Zhou, Y., Li, J. X., Zhu, S., & Lu, W. P. (2021) · Molecules · doi:10.3390/molecules26237241 · Cited by 20 · see citing works

Development of Human Carbonic Anhydrase II Heterobifunctional Degraders

O’Herin, C., Moriuchi, Y. W., Bemis, T. A., Kohlbrand, A. J., Burkart, M. D., & Cohen, S. M. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c01843 · Cited by 20 · see citing works

Tackling drug resistance in ovarian cancer with epigenetic targeted drugs

Zhao, L., Guo, H., Chen, X., Zhang, W., He, Q., Ding, L., & Yang, B. W. (2022) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2022.175071 · Cited by 17 · see citing works

Exploring the landscape of post-translational modification in drug discovery

Cao, Y., Yu, T., Zhu, Z., Zhang, Y., Sun, S., Li, N., Gu, C., & Yang, Y. (2024) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2024.108749 · Cited by 15 · see citing works

PROTACs: Promising Approaches for Epigenetic Strategies to Overcome Drug Resistance

Giardina, S. F., Valdambrini, E., Warren, J. D., & Barany, F. (2021) · Current Cancer Drug Targets · doi:10.2174/1568009621666210203110857 · Cited by 14 · see citing works

Cereblon: promise and challenges for combating human diseases

Kim, H. K., Seol, J. E., Ahn, S. W., Jeon, S., Park, C., & Han, J. (2021) · Pflügers Archiv - European Journal of Physiology · doi:10.1007/s00424-021-02624-0 · Cited by 14 · see citing works

From classic medicinal chemistry to state‐of‐the‐art interdisciplinary medicine: Recent advances in proteolysis‐targeting chimeras technology

Zhao, X., Chen, Y., Su, H., & Zhang, L. (2023) · Interdisciplinary medicine · doi:10.1002/inmd.20230004 · Cited by 14 · see citing works

Proteolysis-Targeting Chimeras (PROTACs) Based on Macrocyclic Tetrapeptides Selectively Degrade Class I Histone Deacetylases 1–3Preprint

Roatsch, M., Vogelmann, A., Herp, D., Jung, M., & Olsen, C. A. (2020) · ChemRxiv · doi:10.26434/chemrxiv.12416303.v1 · Cited by 14 · see citing works

MDM2 Antagonist Idasanutlin Reduces HDAC1/2 Abundance and Corepressor Partners but Not HDAC3

Smalley, J. P., Cowley, S. M., & Hodgkinson, J. T. (2023) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.3c00449 · Cited by 12 · see citing works

Combinatorial Ubiquitination REal-time PROteolysis (CURE-PROs): A Modular Platform for Generating Reversible, Self-Assembling Bifunctional Targeted Degraders

Giardina, S. F., Valdambrini, E., Singh, P. K., Bacolod, M. D., Babu-Karunakaran, G., Peel, M. R., Warren, J. D., & Barany, F. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c02097 · Cited by 12 · see citing works

Replacing a Cereblon Ligand by a DDB1 and CUL4 Associated Factor 11 (DCAF11) Recruiter Converts a Selective Histone Deacetylase 6 PROTAC into a Pan‐Degrader

Feller, F., Weber, H., Miranda, M., Honin, I., Hanl, M., & Hansen, F. K. (2025) · ChemMedChem · doi:10.1002/cmdc.202500035 · Cited by 12 · see citing works

PROTACs targeting epigenetic proteins

Zhang, C., He, Y., Sun, X., Wei, W., Liu, Y., & Rao, Y. (2023) · Acta Materia Medica · doi:10.15212/amm-2023-0039 · Cited by 11 · see citing works

Proteasomal and lysosomal degradation for specific and durable suppression of immunotherapeutic targets

Wang, Y., Deng, S., & Xu, J. (2020) · Cancer Biology and Medicine · doi:10.20892/j.issn.2095-3941.2020.0066 · Cited by 10 · see citing works

Targeting reversible post-translational modifications with PROTACs: a focus on enzymes modifying protein lysine and arginine residues

Pichlak, M., Sobierajski, T., Błażewska, K. M., & Gendaszewska‐Darmach, E. (2023) · Journal of Enzyme Inhibition and Medicinal Chemistry · doi:10.1080/14756366.2023.2254012 · Cited by 10 · see citing works

The Allosteric Regulator Inositol Phosphate Dramatically Affects the Efficacy and Selectivity of Inhibitors for Different HDAC Complexes

Pytel, W. A., Patel, U., Smalley, J. P., Millard, C. J., Brown, E. A., Pavan, A. R., Wang, S., Kalin, J. H., dos Santos, J. L., Cole, P. A., et al. (2025) · Journal of the American Chemical Society · doi:10.1021/jacs.5c08929 · Cited by 10 · see citing works

Epigenetic therapy meets targeted protein degradation: HDAC-PROTACs in cancer treatment

Hussain, M. S., Zhang, L., Rana, A. J., Maqbool, M., Ashique, S., Khan, Y., Jakhmola, V., Hanbashi, A., Mawkili, W., & Khan, G. (2025) · Future Medicinal Chemistry · doi:10.1080/17568919.2025.2533113 · Cited by 9 · see citing works

PROTAC‐Based HDAC Degradation: A Paradigm Shift in Targeted Epigenetic Therapies

Himaja, A., Halder, D., Banerjee, S., Biswas, S., Adhikari, N., & Ghosh, B. (2025) · ChemMedChem · doi:10.1002/cmdc.202500203 · Cited by 9 · see citing works

Cereblon-recruiting proteolysis targeting chimeras (PROTACs) can determine the selective degradation of HDAC1 over HDAC3

Pavan, A. R., Smalley, J. P., Patel, U., Pytel, W. A., dos Santos, J. L., Cowley, S. M., Schwabe, J. W. R., & Hodgkinson, J. T. (2024) · Chemical Communications · doi:10.1039/d4cc05138f · Cited by 9 · see citing works

Probing class I histone deacetylases (HDAC) with proteolysis targeting chimera (PROTAC) for the development of highly potent and selective degraders

Ibrahim, H. S., Guo, M., Hilscher, S., Erdmann, F., Schmidt, M., Schutkowski, M., Sheng, C., & Sippl, W. (2024) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2024.107887 · Cited by 8 · see citing works

Structural Modifications and Prospects of Histone Deacetylase (HDAC) Inhibitors in Cancer

Chen, Y., Su, J., Li, S., Chen, F., Zhang, Y., Wang, X., Zhang, Y., Wang, X., Yuan, Z., Ren, S., et al. (2025) · Current Medicinal Chemistry · doi:10.2174/0109298673332285241104091609 · Cited by 7 · see citing works

Targeted Degradation of Class 1 HDACs With PROTACs is Highly Effective at Inducing DLBCL Cell Death

Alraddadi, A. M., Smalley, J. P., Alzahrani, W., Saleh, A., Al-Mansour, F. S. H., He, B., Cao, T. H., Jayne, S., Dyer, M. J. S., Hodgkinson, J. T., et al. (2025) · eJHaem · doi:10.1002/jha2.70127 · Cited by 7 · see citing works

Proteasomal Degradation of Zn-Dependent Hdacs: The E3-Ligases Implicated and the Designed Protacs That Enable Degradation

Márquez-Cantudo, L., Ramos, A., Coderch, C., & de Pascual‐Teresa, B. (2021) · Molecules · doi:10.3390/molecules26185606 · Cited by 7 · see citing works

Proteolysis-Targeting Chimeras (PROTACs) Based on Macrocyclic Tetrapeptides Selectively Degrade Class I Histone Deacetylases 1–3Preprint

Roatsch, M., Vogelmann, A., Herp, D., Jung, M., & Olsen, C. A. (2020) · ChemRxiv · doi:10.26434/chemrxiv.12416303 · Cited by 6 · see citing works

Medicinal chemistry approaches to the discovery and development of p300/CBP inhibitors for cancer therapy

Wang, H., Song, D., Miao, M., Wu, S., Wang, J., Huang, Z., & Ding, H. (2025) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2025.117959 · Cited by 5 · see citing works

HDAC6 mediates tumorigenesis during mitosis and the development of targeted deactivating agents

Peng, J., Liu, H., Liu, Y., Liu, J., Zhao, Q., Liu, W., Niu, H., Xue, H., Sun, J., & Wu, J. (2024) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2024.107818 · Cited by 5 · see citing works

Solid-phase synthesis of cereblon-recruiting selective histone deacetylase 6 degraders (HDAC6 PROTACs) with anti-leukemic activityPreprint

Sinatra, L., Yang, J., Schliehe‐Diecks, J., Dienstbier, N., Vogt, M., Gebing, P., Bachmann, L. M., Sönnichsen, M., Lenz, T., Stühler, K., et al. (2022) · ChemRxiv · doi:10.26434/chemrxiv-2022-dntx4-v2 · Cited by 5 · see citing works

Multitargeted protein degradation: Integrating small-molecule, biomacromolecular, and nano-PROTACs for paradigm shifts in drug discovery

Yang, J., Zhang, Y., Zhang, M., Xing, D., & Wang, C. (2025) · Materials Today Advances · doi:10.1016/j.mtadv.2025.100644 · Cited by 3 · see citing works

Hydroxamic Acids Immobilized on Resins (HAIRs): Synthese von Dual‐Target‐HDAC‐Inhibitoren und HDAC‐PROTACs

Sinatra, L., Bandolik, J. J., Roatsch, M., Sönnichsen, M., Schoeder, C. T., Hamacher, A., Schöler, A., Borkhardt, A., Meiler, J., Bhatia, S., et al. (2020) · Angewandte Chemie · doi:10.1002/ange.202006725 · Cited by 3 · see citing works

Rise of the Chromodomain Helicase DNA‐Binding (CHD) Chromatin Remodelling Machines

Alendar, A. (2023) · Wiley eBooks · doi:10.1002/9780470015902.a0029448 · Cited by 3 · see citing works

Synthetic and structure–activity studies of SP2577 and TCP towards LSD1 targeting PROTACs

Coulson, M. E., Norris, J. K. S., Smith, S. A., Smalley, J. P., Schwabe, J. W. R., Cowley, S. M., & Hodgkinson, J. T. (2025) · RSC Medicinal Chemistry · doi:10.1039/d5md00420a · Cited by 2 · see citing works

Chromatin Regulatory Targets for Anticancer Therapeutics

Barta, P. A., Carter, T. R., & Erb, M. A. (2025) · Chemical Reviews · doi:10.1021/acs.chemrev.5c00231 · Cited by 2 · see citing works

Synthesis of a HDAC inhibitor–nanogold probe for cryo-EM visualization in class I HDAC co-repressor complexes

Pytel, W. A., Schwabe, J. W. R., & Hodgkinson, J. T. (2026) · Beilstein Journal of Organic Chemistry · doi:10.3762/bjoc.22.35 · Cited by 2 · see citing works

Selective degradation of TBK1 uncovers mechanistic insights into blocking ccRCC progression

Liao, C., Lyu, S., Johnson, R. L., Shang, T., Wang, X., Gildor, N., Li, S., Williams, N. S., James, L. I., Hu, L., et al. (2026) · Cell chemical biology · doi:10.1016/j.chembiol.2026.03.013 · Cited by 2 · see citing works

Histone Deacetylase Meets Protein Degradation: Accelerating Anticancer Drug Discovery

Wang, J.-J., Gao, Y., Ji, X.-Q., Yin, J.-Y., Zhang, M., Wang, B., Liu, H., Feng, S., Wang, N., Lu, G., et al. (2026) · Medicinal Research Reviews · doi:10.1002/med.70052 · Cited by 2 · see citing works

Construction of polydopamine nanomedicine for dual inhibition and degradation of histone deacetylases in cancer cells

Ding, X., Hu, M., Duan, C., Zhao, S., Zhang, J. Z., Liu, Y., Xu, J., Sun, M., & Hu, Y. (2025) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2025.144340 · Cited by 2 · see citing works

PROTACs in cancer therapy: targeted degradation of GPX4, PARP and epigenetic regulators

Periyasamy, S., Jarrett, T., Truong, J., & Skouta, R. (2026) · Journal of Enzyme Inhibition and Medicinal Chemistry · doi:10.1080/14756366.2026.2636394 · Cited by 1 · see citing works

Epigenetic strategies for fetal hemoglobin induction in sickle cell disease

de Souza, M. M., Pavan, A. R., Pastre, V. G. D. F., Gini, A. L. R., Silva, R. D. A., Lanaro, C., de Albuquerque, D. M., Costa, F. F., Scarim, C. B., Hodgkinson, J. T., et al. (2026) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2026.119186 · Cited by 1 · see citing works

Optimization of Class I Histone Deacetylase PROTACs Reveals that HDAC1/2 Degradation is Critical to Induce Apoptosis and Cell Arrest in Cancer Cells

Smalley, J. P., Baker, I. M., Pytel, W. A., Lin, L., Bowman, K. J., Schwabe, J. W. R., Cowley, S. M., & Hodgkinson, J. T. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c02179 · Cited by 84 · see citing works

Probing class I histone deacetylases (HDAC) with proteolysis targeting chimera (PROTAC) for the development of highly potent and selective degraders

Ibrahim, H. S., Guo, M., Hilscher, S., Erdmann, F., Schmidt, M., Schutkowski, M., Sheng, C., & Sippl, W. (2024) · Digitalen Hochschulbibliothek Sachsen-Anhalt (Universitäts- und Landesbibliothek Sachsen-Anhalt) · doi:10.25673/117399

Proteolysis-Targeting Chimeras (PROTACs) Based on Macrocyclic Tetrapeptides Selectively Degrade Class I Histone Deacetylases 1–3Preprint

Roatsch, M., Vogelmann, A., Herp, D., Jung, M., & Olsen, C. A. (2020) · ChemRxiv · doi:10.26434/chemrxiv.12416303.v1 · Cited by 14 · see citing works

Selective degradation of histone deacetylase 8 mediated by a proteolysis targeting chimera (PROTAC)

Chotitumnavee, J., Yamashita, Y., Takahashi, Y., Takada, Y., Iida, T., Oba, M., Itoh, Y., & Suzuki, T. (2022) · Chemical Communications · doi:10.1039/d2cc00272h · Cited by 57 · see citing works

Comprehensive Transcriptomic Analysis of Novel Class I HDAC Proteolysis Targeting Chimeras (PROTACs)

Baker, I. M., Smalley, J. P., Sabat, K. A., Hodgkinson, J. T., & Cowley, S. M. (2022) · Biochemistry · doi:10.1021/acs.biochem.2c00288 · Cited by 32 · see citing works